Dementia Drugs Market - Global Forecast, 2022 - 2028

Dementia Drugs Market - Global Forecast, 2022 - 2028

Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.
Market Dynamics
Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2021, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients.
Key features of the study:
This report provides in-depth analysis of the dementia drugs market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global dementia drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, market expansion, and marketing tactics
The global dementia drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for dementia drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Dementia Drugs Market, By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
Global Dementia Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Global Dementia Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
MAO Inhibitors
Cholinesterase Inhibitors
Glutamate Inhibitors
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Company Profiles
Eisai, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Janssen Pharmaceuticals, Inc.
Biogen Pharmaceuticals
Forest Laboratories, Inc.
Eli Lilly and Company
Novartis AG
Sanofi S.A.
AstraZeneca GmbH
Hoffmann-La Roche
Merck & Co., Inc.
Valeant Pharmaceutical International
Pfizer Inc.
Teva Pharmaceuticals Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.